Literature DB >> 19032397

Patients' preference for radiotherapy fractionation schedule in the palliation of symptomatic unresectable lung cancer.

J I Tang1, T P Shakespeare, J J Lu, Y H Chan, K M Lee, L C Wong, R K Mukherjee, M F Back.   

Abstract

The palliative radiotherapeutic management of unresectable non-small-cell lung cancer is controversial, with various fractionation (Fx) schedules available. We aimed to determine patient's choice of Fx schedule after involvement in a decision-making process using a decision board. A decision board outlining the various advantages and disadvantages apparent in the Medical Research Council study of Fx schedules (17 Gy in two fractions vs 39 Gy in 13 fractions) was discussed with patients who met Medical Research Council eligibility criteria. Patients were then asked to indicate their preferred Fx schedules, reasons and their level of satisfaction with being involved in the decision-making process. Radiation oncologists (RO) could prescribe radiotherapy schedules irrespective of patients' preferences. Of 92 patients enrolled, 55% chose the longer schedule. English-speaking patients were significantly more likely to choose the longer schedule (P = 0.02, 95% confidence interval: 1.2-7.6). Longer Fx was chosen because of longer survival (90%) and better local control (12%). Shorter Fx was chosen for shorter overall treatment duration (80%), cost (61%) and better symptom control (20%). In all, 56% of patients choosing the shorter schedule had their treatment altered by the treating RO, whereas only 4% of patients choosing longer Fx had their treatment altered (P < 0.001). Despite this, all (100%) patients were satisfied with being involved in the decision-making process. The decision board was useful in aiding decision-making, with both Fx schedules being acceptable to patients. Interestingly, despite the longer average survival associated with longer Fx, nearly half of the patients believed that this was not as important as a shorter duration of treatment and lower cost. Despite patients' preferences, there were significant alterations of preferred schedules because of RO's own biases.

Entities:  

Mesh:

Year:  2008        PMID: 19032397     DOI: 10.1111/j.1440-1673.2008.02002.x

Source DB:  PubMed          Journal:  J Med Imaging Radiat Oncol        ISSN: 1754-9477            Impact factor:   1.735


  6 in total

1.  Survival and prognostic factors after moderately hypofractionated palliative thoracic radiotherapy for non-small cell lung cancer.

Authors:  B van Oorschot; B Assenbrunner; M Schuler; G Beckmann; M Flentje
Journal:  Strahlenther Onkol       Date:  2014-01-12       Impact factor: 3.621

2.  Choosing between conventional and hypofractionated prostate cancer radiation therapy: Results from a study of shared decision-making.

Authors:  Thomas P Shakespeare; Justin Westhuyzen; Tracy Lim Yew Fai; Noel J Aherne
Journal:  Rep Pract Oncol Radiother       Date:  2020-01-09

3.  Availability and effectiveness of decision aids for supporting shared decision making in patients with advanced colorectal and lung cancer: Results from a systematic review.

Authors:  Inge Spronk; Maartje C Meijers; Marianne J Heins; Anneke L Francke; Glyn Elwyn; Anne van Lindert; Sandra van Dulmen; Liesbeth M van Vliet
Journal:  Eur J Cancer Care (Engl)       Date:  2019-05-08       Impact factor: 2.328

4.  Palliative thoracic radiotherapy in lung cancer: An American Society for Radiation Oncology evidence-based clinical practice guideline.

Authors:  George Rodrigues; Gregory M M Videtic; Ranjan Sur; Andrea Bezjak; Jeffrey Bradley; Carol A Hahn; Corey Langer; Keith L Miller; Benjamin J Moeller; Kenneth Rosenzweig; Benjamin Movsas
Journal:  Pract Radiat Oncol       Date:  2011-04-08

Review 5.  The availability and effectiveness of tools supporting shared decision making in metastatic breast cancer care: a review.

Authors:  Inge Spronk; Jako S Burgers; François G Schellevis; Liesbeth M van Vliet; Joke C Korevaar
Journal:  BMC Palliat Care       Date:  2018-05-11       Impact factor: 3.234

6.  Clinical management of pain in advanced lung cancer.

Authors:  Claribel P L Simmons; Nicholas Macleod; Barry J A Laird
Journal:  Clin Med Insights Oncol       Date:  2012-10-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.